Results 111 to 120 of about 204,846 (354)

Artificial Intelligence in Systemic Sclerosis: Clinical Applications, Challenges, and Future Directions

open access: yesArthritis Care &Research, EarlyView.
Systemic sclerosis (SSc) is a rare autoimmune disease defined by immune dysregulation, vasculopathy, and progressive fibrosis of the skin and internal organs. Despite advances in care, major complications such as interstitial lung disease (ILD) and myocardial involvement remain the leading causes of morbidity and mortality.
Cristiana Sieiro Santos   +2 more
wiley   +1 more source

The risk of individual autoantibodies, autoantibody combinations and levels for arthritis development in Clinically Suspect Arthralgia

open access: yesRheumatology, 2017
Introduction Autoantibody testing is helpful to predict the risk of progression to clinical arthritis in subjects at risk. Previous longitudinal studies have mainly selected autoantibody-positive arthralgia patients and, consequently, the predictive ...
R. T. ten Brinck   +6 more
semanticscholar   +1 more source

Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis

open access: yesArthritis Care &Research, EarlyView.
Objective This study aims to identify factors associated with patient global assessment (PtGA) and physician global assessment (PhGA) and discordance between them in systemic sclerosis (SSc). Methods Data from adults with early SSc (<5 years) from the Collaborative National Quality and Efficacy Registry were included.
Ellen Romich   +35 more
wiley   +1 more source

Clinical Significance and Diagnostic Value of Survivin Autoantibody in Non-small Cell Lung Cancer Patients

open access: yesChinese Journal of Lung Cancer, 2010
Background and objective Lung cancer is one of the most common cancers worldwide and causes more deaths per year than other cancers. Autoantibody was one hotspot in tumor marker research.
Li MA   +5 more
doaj  

Elevation of TP53 Autoantibody Prior to CA125 in Preclinical Invasive Epithelial Ovarian Cancer

open access: yesClinical Cancer Research, 2017
Purpose: The TP53 tumor-suppressor gene is mutated in >95% of high-grade serous ovarian cancers. Detecting an autologous antibody response to TP53 that might improve early detection.
Wei-Lei Yang   +14 more
semanticscholar   +1 more source

Immunosuppressive Drug Use in Limited Systemic Sclerosis: An International Survey

open access: yesArthritis Care &Research, EarlyView.
Objective Current guidelines recommend immunosuppressive treatment for diffuse cutaneous systemic sclerosis but are less clear on their use in limited cutaneous systemic sclerosis (lcSSc) in the absence of internal organ complications. We conducted an international survey to understand current immunosuppressive drug prescribing patterns in lcSSc ...
Sabrina Hoa   +3 more
wiley   +1 more source

Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis

open access: yesActa Dermato-Venereologica, 2018
Anti-transcriptional intermediary factor-1γ (TIF-1γ) autoantibody may be associated with cancer in adult patients with dermatomyositis. The aim of this study was to evaluate the risk of cancer in the presence of anti-TIF-1γ autoantibody in adult ...
Marion Best   +5 more
doaj   +1 more source

The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes

open access: yesJournal of Internal Medicine, 2016
The aim of this review was to summarize recent advances in the understanding of the clinical and autoantibody phenotypes, their associated outcomes and the pathogenesis of the juvenile idiopathic inflammatory myopathies (JIIMs).
L. Rider, K. Nistala
semanticscholar   +1 more source

[Which clinical symptoms suggest distinct autoantibody measurements?]

open access: yes, 2010
The detection of autoantibodies is an important cornerstone in the diagnosis of systemic autoimmune disorders such as autoimmune connectivitides and small vessel vasculitides.
Seitz, Michael
core  

US prevalence of a detectable serum autoantibody, NHANES 1988–1994.

open access: yes, 2020
US prevalence of a detectable serum autoantibody, NHANES 1988–1994.
Frederick W. Miller (454042)   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy